DaunoXome liposomal daunorubicin data

NXTR presented Phase II data on 11 women with newly diagnosed metastatic breast cancer. Patients received 100mg/m2 of DaunoXome every three weeks for up to 24 weeks, showing tumor responses with minimal toxicity.

As reported at the San Antonio Breast Cancer Symposium, this moderate dose gave a partial response in 3 patients, stabilized disease in 7, and gave no benefit for 1 patient. ...